Item Posts Archive - Page 45 of 1770 - Medivizor
Navigation Menu

Is the addition of low-dose prednisolone more beneficial than harmful to older patients with rheumatoid arthritis?

Is the addition of low-dose prednisolone more beneficial than harmful to older patients with rheumatoid arthritis?

Posted by on Oct 16, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell This study assessed the effectiveness and safety of daily administered prednisolone (Prelone) at a dose of 5 mg, as an add-on to the standard of care (SOC) in older patients with rheumatoid arthritis (RA). The authors concluded that low-dose prednisolone added to SOC had long-term benefits in these patients with a favorable balance of...

Read More

Can walking speed be improved with foot-ankle therapeutic exercises in patients with diabetic nerve disease?

Can walking speed be improved with foot-ankle therapeutic exercises in patients with diabetic nerve disease?

Posted by on Oct 16, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the effects of foot-ankle therapeutic exercises on daily physical activity and gait (walking) speed in people with diabetic peripheral neuropathy (DPN). The data showed that at 12 weeks, these exercises led to improvements in fast walking speeds and quality of life compared to usual care. Some background...

Read More

How safe and effective is dapagflozin in patients with type 2 diabetes based on blood pressure levels?

How safe and effective is dapagflozin in patients with type 2 diabetes based on blood pressure levels?

Posted by on Oct 16, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study analyzed the safety and effectiveness of dapagliflozin (Farxiga) in patients with type 2 diabetes (T2D) across different ranges of baseline systolic blood pressure (SBP; blood pressure when the heart beats). The data suggested that dapagliflozin reduced the risk of hospitalization for heart failure (HHF) and kidney-related...

Read More

Comparing the effectiveness and safety of an early versus a delayed invasive strategy in patients with non-ST elevation acute coronary syndrome.

Comparing the effectiveness and safety of an early versus a delayed invasive strategy in patients with non-ST elevation acute coronary syndrome.

Posted by on Oct 13, 2022 in Coronary artery disease | 0 comments

In a nutshell This study compared the effectiveness and safety of an early and a delayed invasive strategy (IS) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). The data showed that there were no significant differences in the risk of death, heart attacks, stroke rates, major bleeding, or revascularization between early and delayed...

Read More